ストックスクリーナーアプリを入手
41.54
1.54%
0.63
前日終値:
$40.91
開ける：
$41.195
24時間の取引高:
607.50K
Relative Volume:
0.20
時価総額：
$7.86B
収益：
$2.83B
当期純損益:
$-1.02B
株価収益率:
-7.539
EPS:
-5.51
ネットキャッシュフロー:
$194.14M
1週間 パフォーマンス:
-12.29%
1か月 パフォーマンス:
-19.97%
6か月 パフォーマンス:
-17.48%
1年 パフォーマンス:
-27.77%
1日の値動き範囲:
$41.20
$41.91
1週間の範囲:
$38.81
$47.58
52週間の値動き範囲:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
EXAS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
41.54 | 7.76B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
473.19 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.53 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
653.45 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
116.36 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.21 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-01-02 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-10-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-08-02 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-05-10 | アップグレード | Craig Hallum | Hold → Buy |
| 2023-05-05 | 開始されました | UBS | Neutral |
| 2023-03-09 | アップグレード | Citigroup | Neutral → Buy |
| 2023-02-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | ダウングレード | Craig Hallum | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2021-11-03 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 繰り返されました | BTIG Research | Buy |
| 2021-07-29 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-29 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-29 | 繰り返されました | Stifel | Buy |
| 2021-06-15 | 開始されました | Raymond James | Strong Buy |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Equal Weight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-29 | ダウングレード | UBS | Buy → Neutral |
| 2020-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-04-02 | 開始されました | Evercore ISI | Outperform |
| 2020-01-10 | 再開されました | BTIG Research | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Dougherty & Company | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-17 | 繰り返されました | BofA/Merrill | Buy |
| 2019-10-01 | 再開されました | Craig Hallum | Buy |
| 2019-09-26 | 開始されました | Oppenheimer | Outperform |
| 2019-02-26 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-09 | 開始されました | UBS | Buy |
| 2018-09-05 | 再開されました | The Benchmark Company | Hold |
| 2018-08-13 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-01-29 | 開始されました | Goldman | Neutral |
| 2018-01-08 | 繰り返されました | The Benchmark Company | Buy |
| 2017-11-13 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | ダウングレード | BTIG Research | Buy → Neutral |
すべてを表示
Exact Sciences Corp (EXAS) 最新ニュース
BTIG lowers Exact Sciences stock price target to $60 on Freenome deal - Investing.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - uk.finance.yahoo.com
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
FY2025 EPS Forecast for Exact Sciences Increased by Analyst - Defense World
Applying Elliott Wave Theory to Exact Sciences CorporationEarnings Impact and Stock Reaction Analysis - Newser
How to read the order book for Exact Sciences CorporationFree Real Time Alerts Based on AI Prediction - Newser
Real time social sentiment graph for Exact Sciences CorporationAI Entry Timing Prediction for Swing Traders - Newser
Real time scanner hits for Exact Sciences Corporation explainedTrading Volume Anomaly Summary and Insight - Newser
Avantax Advisory Services Inc. Acquires 1,259 Shares of Exact Sciences Corporation (NASDAQ:EXAS) - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Exact Sciences - Defense World
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $60 to $70 - 富途牛牛
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock By Investing.com - Investing.com Australia
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock - Investing.com
Exact Sciences (NASDAQ:EXAS) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Exact Sciences Corp’s Strong Earnings Call Highlights - TipRanks
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst - AOL.com
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal? - Investor's Business Daily
Why Is Exact Sciences Stock Tumbling Thursday?Exact Sciences (NASDAQ:EXAS) - Benzinga
Exact Sciences Earnings: Blood-Based Test Misses Cutoff for Medicare Reimbursement - Morningstar
Exact Sciences Leads the Colorectal Cancer Screening Market, but Uncertainty Lies Ahead - Morningstar
Exact Sciences stock price target lowered to $46 at RBC on growth concerns - Investing.com Canada
Bernstein SocGen lowers Exact Sciences stock price target to $60 - Investing.com
Exact Sciences (EXAS) Secures Rights to Freenome's Cancer Screening Tests - GuruFocus
UBS Adjusts Exact Sciences Price Target to $53 From $61, Maintains Neutral Rating - MarketScreener
Exact Sciences stock price target lowered to $66 by TD Cowen after blood test setback - Investing.com
Piper Sandler reiterates Overweight rating on Exact Sciences stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Exact Sciences stock - Investing.com
Exact Sciences Reports Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
Exact Sciences Corp. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Exact Sciences price target lowered to $55 from $65 at Barclays - TipRanks
Exact Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Exact Sciences to acquire US rights for Freenome’s blood-based CRC test - Yahoo Finance
Exact Sciences: Q2 Earnings Snapshot - Manistee News Advocate
Earnings call transcript: Exact Sciences Q2 2025 beats EPS forecasts - Investing.com
Exact Sciences Q2 2025 slides: Revenue jumps 16%, guidance raised on strong performance - Investing.com Canada
Exact Sciences Corp. Reports Strong Q2 2025 Results - TipRanks
Exact Sciences lays off 4% of company including Madison positions - WMTV 15 NEWS
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer | Newswise - Newswise
Exact Sciences (EXAS) Q2 Revenue Up 16% - The Globe and Mail
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2% - Yahoo Finance
Exact Sciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Exact Sciences shares plunge despite earnings beat By Investing.com - Investing.com Nigeria
Key External Factors That Drive Exact Sciences Corporation Stock Price MovementsReal Stock Picks With Setup Verification - Newser
Exact Sciences shares plunge despite earnings beat - Investing.com
EXACT Sciences earnings beat by $0.12, revenue topped estimates - Investing.com
Exact Sciences Announces Collaboration with Freenome Holdings - TipRanks
Exact Sciences acquires rights to Freenome’s blood-based CRC tests By Investing.com - Investing.com South Africa
Exact Sciences acquires rights to Freenome’s blood-based CRC tests - Investing.com
Earnings Flash (EXAS) Exact Sciences Corp. Posts Q2 Adjusted EPS $0.22 per Share - MarketScreener
Exact Sciences Corp (EXAS) 財務データ
収益
当期純利益
現金流量
EPS
Exact Sciences Corp (EXAS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Aug 05 '25 |
Option Exercise |
0.00 |
5,350 |
0 |
27,943 |
1.37%
0.59%
大文字化:
|
ボリューム (24 時間):